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Glioblastomas show heterogeneous histological features.These distinct phenotypic states
are thought to be associated with the presence of glioma stem cells (GSCs), which are
highly tumorigenic and self-renewing sub-population of tumor cells that have different func-
tional characteristics. Differentiation of GSCs may be regulated by multi-tiered epigenetic
mechanisms that orchestrate the expression of thousands of genes. One such regulatory
mechanism involves functional non-coding RNAs (ncRNAs), such as microRNAs (miRNAs);
a large number of ncRNAs have been identiﬁed and shown to regulate the expression
of genes associated with cell differentiation programs. Given the roles of miRNAs in
cell differentiation, it is possible they are involved in the regulation of gene expression
networks in GSCs that are important for the maintenance of the pluripotent state and for
directing differentiation. Here, we review recent ﬁndings on ncRNAs associated with GSC
differentiation and discuss how these ncRNAs contribute to the establishment of tissue
heterogeneity during glioblastoma tumor formation.
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INTRODUCTION
Gliomas are the most common type of malignant primary brain
tumor with an incidence of ∼5 cases per 100,000 persons (Wen
and Kesari, 2008). Glioblastoma multiforme (GBM) is the high-
est grade glioma (grade 4). Despite advances in treatment using
combinations of surgery, radiotherapy, and chemotherapy, GBM
confers an average life expectancy of around 14months fromdiag-
nosis (Wen and Kesari, 2008). Accumulating evidence indicates
that the presence of a subset of cells with the potential to ini-
tiate and maintain growth of gliomas might be crucial for their
resistance to conventional therapies (Hadjipanayis and Van Meir,
2009). These cells are designated as glioma stem cells (GSCs; Galli
et al., 2004; Singh et al., 2004; Lee et al., 2006; Penuelas et al., 2009;
Mazzoleni et al., 2010). GSCs and normal neural stem cells appear
to share common features including self-renewal and the capa-
bility of differentiating into multiple lineages. Intriguingly, recent
studies revealed that in addition to GSCs differentiating into non-
GSCs, the reverse process might also occur (Gupta et al., 2011;
Natsume et al., 2013). This phenotypic plasticity between the GSC
and non-GSC states may be regulated by signals within the tumor
microenvironment.
Microenvironmental signals, such as sonic Hedgehog (SHH),
Wnt, and Notch, have been shown to regulate the properties
of cancer stem cells (Reya and Clevers, 2005; Fan et al., 2010;
Takebe et al., 2011). SHH has a critical role in the maintenance of
GSCs by regulating so-called “stemness” genes and has also been
found to be activated in many high-grade gliomas (Clement et al.,
2007; Takezaki et al., 2011). The Wnt/β-catenin pathway has been
implicated in the role of GSCs in gliomagenesis through tumor
proliferation and invasion (Nager et al., 2012). Notch signaling
has been shown to promote GSC self-renewal and to suppress GSC
differentiation (Shih and Holland, 2006; Fan et al., 2010; Hu et al.,
2011). Genes in the receptor tyrosine kinase (RTK) family medi-
ate several oncogenic growth factor pathways, such as epidermal
growth factor receptor (EGFR) and platelet-derived growth factor
receptor (PDGFR), that have been linked to malignancy, angio-
genesis, self-renewal, and multipotency. Recently, it was shown
that constitutively activated EGFRvIII expression and loss of the
phosphatase and tensin (PTEN) protein in murine neural stem
cells results in the formation of glial tumors (Li et al., 2009a).
PDGF overexpression has also been implicated in gliomagenesis,
and PDGFs can inhibit glial cell differentiation (Fomchenko and
Holland, 2007).
Recent advanced technology to identify non-coding RNAs
using microarrays or next generation sequencing technologies
provide extraordinary abundance of novel data in genome wide-
scale and revealed deeper insights into the biology of non-cording
RNAs (ncRNAs). More than 90% of the human genome appears
to be transcribed and transcription is not limited to protein-
coding regions (Birney et al., 2007). Some ncRNAs may play key
regulatory and functional roles. Indeed, signiﬁcant numbers of
ncRNAs, such as microRNAs (miRNAs, miRs) and long non-
coding RNAs (lncRNAs), are regulated during development in a
cell-type speciﬁc manner, and are associated with multiple cell
functions (Kapranov et al., 2007). miRNAs are the short non-
coding endogenous RNAs that post-transcriptionally regulate the
expression of a large number of genes (Bartel, 2004). miRNAs
play important roles in a wide variety of physiological and patho-
logical processes including tumor formation. Aberrant expression
of miRNA can induce tumor suppression or can have an onco-
genic effect resulting in tumor formation (Medina and Slack,
2008; Gangaraju and Lin, 2009). lncRNAs are functional ncRNAs
that are potentially key regulators not only of cellular differen-
tiation and proliferation, but may also have tumor suppressive
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or oncogenic functions in many types of cancer (Esteller, 2011;
Wapinski and Chang, 2011; Hu et al., 2012; Zhang et al., 2013).
In this review, we provide a summary of the current under-
standing of miRNAs and lncRNAs in gliomas with a focus on their
roles in GSCs.
miRNAs IN GSC DIFFERENTIATION
miRNAs are short sequences of 17–25 nucleotides that are not
transcribed but have a regulatory function. An RNase III enzyme
converts pri-miRNA into pre-miRNA hairpin transcripts that are
processed into mature miRNAs and incorporated into a ribonu-
cleoprotein complex called the RNA-induced silencing complex
(RISC). The RISC and associated mature miRNA then binds to
mRNAand causes a physical block to translation (Ambros and Lee,
2004; Bartel, 2004). Many miRNAs form imperfectly complemen-
tary stem-loop structures on the sense strand of the target mRNA.
Thus, each miRNA can target multiple mRNA species through
recognition of complementary sequences. Upregulation of mature
miRNAs may occur as a consequence of transcriptional activation
or ampliﬁcation of the corresponding pre-miRNA locus, whereas
downregulation of miRNAs may result from epigenetic silencing
or deletion of the corresponding region (Schickel et al., 2008).
Although dysregulation of the miRNA-mRNA network has been
reported in glioblastoma, little attention has so far been paid to its
role in GSCs (Godlewski et al., 2010a). In this section, we describe
the information available on the signiﬁcance of miRNAs in GSCs
(Table 1).
miR-17-92 CLUSTER
The miR-17-92 cluster is thought to be involved in the regulation
of GSC differentiation, apoptosis, and proliferation (Ernst et al.,
2010). The level of transcripts from miR-17-92 clusters are signif-
icantly higher in primary astrocytic tumors than in normal brain
tissues and increase signiﬁcantly with tumor grade progression.
A High-level ampliﬁcation of the miR-17-92 locus has also been
found in glioblastoma specimens. InhibitionofmiR-17-92 induces
apoptosis and decreases cell proliferation in GSCs. mir-17-92
inhibition is also associated with induction of cyclin-dependent
kinase inhibitor 1A (CDKN1A), E2F transcription factor 1 (E2F1),
PTEN, and connective tissue growth factor (CTGF). Of these,
the CTGF gene was shown to be a direct target of miR-17-92
in GSCs.
When GSCs are exposed to the differentiation-promoting con-
ditions, downregulation of the oncogenic miR-17-92 cluster is
directly related to the concomitant upregulation of CTGF (Ernst
et al., 2010).
miR-124 AND miR-137
The initial analysis of miR-124 showed that it promotes neuronal
differentiation by targeting the polypyrimidine tract-binding pro-
tein 1 (PTBP1) that encodes a global repressor of alternative
pre-mRNA splicing; miR reduces the level of PTBP1, which results
in an increase in the production of nervous system-speciﬁc alter-
nativeRNAsplicing andpromotes thedifferentiationof progenitor
cells to mature neurons (Makeyev et al., 2007). Subsequent anal-
ysis showed that both miR-124 and miR-137 are downregulated
in high-grade gliomas and up-regulated during adult neural stem
cell differentiation (Silber et al., 2008). Transfection of miR-124 or
miR-137 inhibits proliferation of GSCs, via suppression of cyclin-
dependent protein kinase 6 (CDK6), and induces morphological
changes in human GSCs and expression of neuronal differenti-
ation markers. Overexpression of miR-124 has consistently been
found to inhibit the CD133+ cell subpopulation of the neuro-
sphere and to downregulate stem cell markers, such as BMI1,
Nanog, andNestin. These effects could be rescued by re-expression
of SNAI2, another direct target of miR-124 (Xia et al., 2012).
miR-451
Analysis of the miRNA proﬁles of GSC (CD133+ cells) and
non-GSC (CD133– cells) populations showed that several miR-
NAs, including miR-451, miR-486, and miR-425, are upregulated
in CD133– cells. Transfection of cells with miR-451 has been
shown to induce disruption of glioblastoma neurospheres (Gal
et al., 2008). Interestingly, this study also showed that SMAD
Table 1 | List of miRNAs dysregulated in GSCs.
MicroRNAs Direct targets Roles in GSC Reference
miR-17-92 cluster CTGF Differentiation (−), proliferation (+), apoptosis (−) Ernst et al. (2010)
miR-451 CAB39 Differentiation (−), proliferation (+), apoptosis (−) Godlewski et al. (2010b)
miR-1275 CLDN11 Differentiation (−), proliferation (+) Katsushima et al. (2012)
miR-138 CASP3, BLCAP, MXD1 Differentiation (−), proliferation (+), apoptosis (−) Chan et al. (2012)
miR-137 CDK6 Differentiation (+), proliferation (−) Silber et al. (2008)
miR-34a MET, NOTCH1, NOTCH2,
CDK6
Differentiation (+), proliferation (−), apoptosis (+) Li et al. (2009b), Guessous et al. (2010)
miR-302-367 cluster CXCR4 Differentiation (+), proliferation (−), invasion (−) Fareh et al. (2012)
miR-124 SNAI2 Differentiation (+), proliferation (−), invasion (−) Xia et al. (2012)
miR-204 SOX4, EPHB2 Differentiation (+), proliferation (−), invasion (−) Ying et al. (2013)
miR-128 BMI1, SUZ12 Differentiation (+), proliferation (−), radiosensitivity (−) Godlewski et al. (2008), Peruzzi et al. (2013)
(+) = increased, (–) = decreased.
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proteins, which are associated with GSC regulation, can upreg-
ulate miR-451 by binding to its promoter region. Thus, there is a
link between miRNAs and well-known stem cell regulating pro-
teins (Piccirillo et al., 2006). Another interesting ﬁnding regarding
miR-451 is that its expression level is correlated with glucose con-
centration. High glucose levels are associated with relatively high
levels of miR-451 expression, which promote cell growth; miR-451
expression levels decrease under low glucose conditions, resulting
in a reduced rate of cell proliferation but an enhanced rate of
cell migration and survival in glioblastomas. This miR-451 effect
is mediated by liver kinase B1 (LKB1). These data indicate that
tumor cells can survive under metabolic stress conditions and
also seek out locations with more favorable growth conditions by
migration inﬂuenced through an LKB1/AMPK pathway mediated
by miR-451 (Godlewski et al., 2010b).
miR-34a
miR-34a is tumor-suppressive and is downregulated in human
glioma tissues; miR-34a directly inhibits the expression of c-
Met, Notch-1, and Notch-2 in GSCs (Li et al., 2009b). Notch is
a critical regulator of cell-fate during development and also of
normal stem cell maintenance (Fan et al., 2006; Shih and Hol-
land, 2006; Fan et al., 2010). Activation of the Notch pathway
enhances the stemness, proliferation, and radioresistance of GSCs
(Wang et al., 2010). Ectopic expression of miR-34a in glioma
cells inhibits cell proliferation, survival, and migration. In addi-
tion, miR-34a induces GSC differentiation as evidenced by the
decreased expressionof stemcellmarkers and increased expression
of differentiation markers (Guessous et al., 2010).
miR-128
Two studies have described a link between miR-128 and the poly-
comb repressor complex (PRC). Two major complexes, PRC1 and
PRC2, are recognized as key epigenetic regulators during devel-
opment (Lund and van Lohuizen, 2004) and are required for
maintaining self-renewal and multi-potential capability (Richly
et al., 2011). The ﬁrst study demonstrated that miR-128 has
a tumor-suppressive function and that this is downregulated
in glioblastoma tissue. miR-128 expression signiﬁcantly reduces
glioma cell proliferation both in vitro and in vivo via downregu-
lation of the oncogene Bmi-1 that is a component of PRC1. In
addition, miR-128 inhibits GSC self-renewal (Godlewski et al.,
2008). The second study showed that miR-128 directly targets
SUZ12, a key component of PRC2. Ectopic expression of miR-
128 in GSCs signiﬁcantly increases their radiosensitivity (Peruzzi
et al., 2013). The PRC has been shown to promote normal and
cancer stem cell self-renewal and is also implicated in GSC reg-
ulation (Abdouh et al., 2009; Suva et al., 2009; Natsume et al.,
2013). The ﬁndings of these various studies therefore indicate that
miR-128 mediates an important epigenetic regulatory pathway
in GSCs.
OTHER miRNAs
Several other miRNAs have been implicated in glioma malig-
nancy. Ectopic expression of the miR-302-367 cluster in GSCs
inhibits the CXCR4 pathway resulting in the suppression of stem-
ness signatures, self-renewal, and cell inﬁltration. Inhibition of
the CXCR4 pathway leads to the disruption of the SHH-GLI-
NANOG network, which is important for cell self-renewal and
tumorigenic properties (Fareh et al., 2012). In bothGSCs andnon-
GSCs, miR-1275 is controlled by a polycomb-mediated silencing
mechanism and regulates expression of the oligodendroglial-
lineage gene claudin 11 (CLDN11). These data illustrate that
miR-1275 is regulated by an epigenetic pathway and that it con-
tributes to the phenotypic diversity of glioblastoma tissues. The
increased insight into the roles of these miRs may provide a bet-
ter understanding of basis for the heterogeneity of glioblastomas
in the context of human neurodevelopment (Katsushima et al.,
2012). Recently, miR-204 was shown to suppress self-renewal, a
stem cell characteristic, and the migration of GSCs by target-
ing the stemness-governing transcriptional factor SOX4 and the
migration-promoting receptor EphB2 (Ying et al., 2013).
LncRNAs IN CANCER
Genome-wide studies showed that there are a large number of
ncRNAs, including a group termed lncRNAs (Birney et al., 2007).
LncRNAs are generally greater than 200 nucleotides and up to
100 kb in length (Mercer et al., 2009). It is known that lncRNAs
are mainly transcribed by RNA polymerase II, are polyadenylated
and spliced (Wu et al., 2008; Mercer et al., 2009; Ponting et al.,
2009). Approximately 15,000 lncRNAs are estimated to occur in
human cells and these are frequently expressed in tissue-speciﬁc
patterns (Derrien et al., 2012). lncRNAs appear to play impor-
tant roles in a wide range of biological cellular processes including
maintenance of stemness, development, and cell survival (Koziol
and Rinn, 2010; Zhang et al., 2013). Currently studies detected
a set of lncRNAs in each disease using RNA immunoprecipi-
tation with RNA binding proteins coupled with computational
approaches.
Long non-coding RNAs are believed to regulate gene expres-
sion through four different pathways (Koziol and Rinn, 2010; Hu
et al., 2012). First, lncRNAs can bind to chromatin modifying pro-
teins (which have a scaffold function) and recruit these proteins
to target loci. These lncRNA complexes can target genes that are
closely situated in the genome (cis-regulation) or genes that are
genomically distant (trans-regulation; Nagano et al., 2008; Pandey
et al., 2008; Zhao et al., 2008; Gupta et al., 2010; Huarte et al., 2010;
Tian et al., 2010; Prensner et al., 2011; Wang et al., 2011). Second,
lncRNAs can act as an RNAdecoy, that is, they can interact directly
with aDNAbinding domain to prevent transcription factors inter-
acting with their DNA targets (Kino et al., 2010; Ng et al., 2012).
Third, lncRNAs can act as an miRNA sponge, that is, they prevent
speciﬁc miRNAs from binding to their target mRNAs by compet-
itive binding (Poliseno et al., 2010; Cesana et al., 2011; Karreth
et al., 2011). Fourth, lncRNAs can bind to speciﬁc combina-
tions of regulatory proteins, such as RNA splicing proteins within
ribonucleoprotein complexes (Tripathi et al., 2010; Ng et al., 2012;
Schor et al., 2012).
There is increasing evidence to show that a set of lncRNAs
is associated with cancer pathogenesis and that these lncRNAs
function as regulators in cancer development (Prensner and Chin-
naiyan, 2011). lncRNAs that are dysregulated in cancers are listed
in Table 2. Below, we provide a brief description of some lncRNAs
that are associated with glioma tumorigenesis.
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MEG3
Maternally expressed gene 3 (MEG3) is a maternally expressed
imprinted gene that can also act as an lncRNA. MEG3 is gen-
erally expressed in normal tissues, and its downregulation by
aberrant DNA methylation has been found in many types of
human cancer (Zhou et al., 2012; Shi et al., 2013). For example,
MEG3 expression in glioma tissues is decreased compared to adja-
cent normal tissues (Wang et al., 2012). The tumor-suppressive
role of MEG3 is supported by the fact that it can associate with
p53 and that this association is required for p53 activation (Lu
et al., 2013). Ectopic expression of MEG3 inhibits cell prolifera-
tion and induced cell apoptosis in glioma cell lines (Wang et al.,
2012).
CRNDE
Colorectal neoplasia differentially expressed (CRNDE) transcripts
are categorized as lncRNAs and have the potential to interact
with chromatin-modifying proteins to regulate gene expres-
sion through epigenetic changes (Ellis et al., 2012). CRNDE is
expressed in the fetal brain and in induced pluripotent stem
cells; the level of expression increases during neuronal differ-
entiation but no transcripts can be detected in the adult brain
(Lin et al., 2011). Intriguingly, CRNDE is highly expressed in
gliomas. The recent study of Ellis et al. demonstrated a direct
interaction betweenCRNDE transcripts and components of PRC2
and the CoREST chromatin-modifying complex. CRNDE pro-
vides speciﬁc functional scaffolds for regulatory complexes, such
as PRC2 and CoREST, and may contribute the maintenance of
pluripotent state as well as neuronal differentiation (Ellis et al.,
2012).
CONCLUDING REMARKS
Following the discovery of cancer stem cells, it became impor-
tant to elucidate the mechanisms and the environmental cues
that control the differentiation of these cells into the diverse
array of cell types that form during tumorigenesis. Epigenetic
dysregulation has recently been shown to change the balance
between differentiation and self-renewal of cortical progenitor
cells and, thereby, to alter the rate and developmental timing of
neurogenesis (Pereira et al., 2010). Given that cancer is a disease
of faulty cellular differentiation, it is likely that aberrant epi-
genetic mechanisms involving ncRNAs are involved in glioma
tumorigenesis. lncRNAs are increasingly important because of
their potential for use in clinical diagnosis and treatment. To
date, however, the functions of only a few lncRNAs have been
elucidated with respect to tumor biology and there are still
many aspects that remain to be resolved. Further investiga-
tions are required to clarify the functional roles of lncRNAs in
order to elucidate the gene regulatory mechanisms in glioma-
genesis. Understanding of the interplays between lncRNAs and
genomes, which are reversible alterations, may offer a novel
opportunity for the development of molecularly targeted ther-
apies. Nevertheless, a better understanding of the glioblastoma
core signaling pathways regulated by ncRNAs and other epige-
netic mechanisms will undoubtedly provide novel therapeutic
targets and strategies with applications in diagnosis and therapy
in glioblastoma.
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